Glenmark Pharmaceuticals U.S. > News

News

Press Releases

Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.

Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting

February 19, 2019

Glenmark to Spin-off its Innovation Business into a New Company in the US

February 14, 2019

Glenmark Pharmaceuticals receives ANDA approval for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg

February 11, 2019

Glenmark Pharmaceuticals receives tentative ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)

February 7, 2019

Glenmark Pharmaceuticals receives tentative ANDA approval for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg

January 24, 2019

News

Search Result :-

Is an investigational new drug that has not been approved for commercial distribution in the United States.

February 19, 2019
Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting

February 14, 2019
Glenmark to Spin-off its Innovation Business into a New Company in the US

February 11, 2019
Glenmark Pharmaceuticals receives ANDA approval for Sevelamer Hydrochloride Tablets, 400 mg and 800 mg

February 7, 2019
Glenmark Pharmaceuticals receives tentative ANDA approval for Fulvestrant Injection, 250 mg/5 mL (50 mg/mL)

January 24, 2019
Glenmark Pharmaceuticals receives tentative ANDA approval for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg

US Media Contact

For media inquiries only, please contact Corporate Communications.
uscomms@glenmarkpharma.com

Investor Relations

For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.

POTASSIUM CHLORIDE EXTENDED RELEASE CAPSULES 750mg RECALL REIMBURSEMENT POLICY

Over-the-counter (OTC)

ACCESSIBLE PRODUCTS

Who We Are

Injectables

OUR GROWING LINE